Skip to main content

Table 3 Phone-based survey of treatment outcomes of EIB and TB-AOI cases - Alberta, 2004–14

From: Program-wide review and follow-up of erythema Induratum of Bazin and tuberculosis-associated ocular inflammation management in a TB low-incidence setting: need for improved treatment candidate selection, therapy standardization, and care collaboration

 

EIB (n = 21)

TB-AOI (n = 20)

Phone Follow-up – no. (%)

n = 13 (62)

n = 11 (55)

Time post ATT – month (year)

 Median

61 (5.1)

49 (4.1)

 IQR

34 (2.8)

48 (4)

Responses

 “Do you still have (EIB/TB-AOI)?”

  Resolved – no. (%)

8 (62)

2 (18)

  Better

2 (15)

3 (28)

  Worse

0 (0)

0 (0)

  No change

3 (23)

6 (54)

 “How did your condition respond to the ATT?”

  Min (< 25% improvement)

1 (8)

8 (73)

  Mod (~ 50%)

1 (8)

1 (9)

  Significantly (~ 75%)

2 (15)

0 (0)

  Complete (100%)

7 (54)

2 (18)

 “How did you tolerate the ATT?”

  Poorly

5 (38)

3 (28)

  Well

5 (38)

2 (18)

  No issue

3 (24)

6 (54)

  1. EI – erythema induratum, TB-AOI – tuberculosis-associated ocular inflammation, ATT – anti-tubercular therapy